235 related articles for article (PubMed ID: 35241549)
1. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
[TBL] [Abstract][Full Text] [Related]
2. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
[TBL] [Abstract][Full Text] [Related]
3. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
[TBL] [Abstract][Full Text] [Related]
4. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
Tanoue K; Tamura S; Kusaba H; Shinohara Y; Ito M; Tsuchihashi K; Shirakawa T; Otsuka T; Ohmura H; Isobe T; Ariyama H; Koreishi S; Matsushita Y; Shimokawa H; Tanaka R; Mitsugi K; Akashi K; Baba E
Sci Rep; 2021 Feb; 11(1):2741. PubMed ID: 33531609
[TBL] [Abstract][Full Text] [Related]
5. Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome.
Ueki Y; Ohshima S; Omata J; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Horii A
Cancer Med; 2023 Nov; 12(22):20810-20820. PubMed ID: 37902133
[TBL] [Abstract][Full Text] [Related]
6. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
[TBL] [Abstract][Full Text] [Related]
7. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab.
Tachinami H; Tomihara K; Yamada SI; Ikeda A; Imaue S; Hirai H; Nakai H; Sonoda T; Kurohara K; Yoshioka Y; Hasegawa T; Naruse T; Niiyama T; Shimane T; Ueda M; Yanamoto S; Akashi M; Umeda M; Kurita H; Miyazaki A; Arai N; Hayashi R; Noguchi M
Br J Oral Maxillofac Surg; 2023 May; 61(4):320-326. PubMed ID: 37061418
[TBL] [Abstract][Full Text] [Related]
9. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab.
Ueda T; Chikuie N; Takumida M; Furuie H; Kono T; Taruya T; Hamamoto T; Hattori M; Ishino T; Takeno S
Acta Otolaryngol; 2020 Feb; 140(2):181-187. PubMed ID: 31825711
[No Abstract] [Full Text] [Related]
10. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
12. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.
Yasumatsu R; Wakasaki T; Hashimoto K; Nakashima K; Manako T; Taura M; Matsuo M; Nakagawa T
Head Neck; 2019 Aug; 41(8):2610-2618. PubMed ID: 30835919
[TBL] [Abstract][Full Text] [Related]
17. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
[TBL] [Abstract][Full Text] [Related]
18. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
20. Post-treatment Neutrophil/Lymphocyte Ratio Is a Prognostic Factor in Head and Neck Cancers Treated With Nivolumab.
Iwasa YI; Kitoh R; Yokota Y; Hori K; Kasuga M; Kobayashi T; Kanda S; Takumi Y
Cancer Diagn Progn; 2024; 4(2):182-188. PubMed ID: 38434918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
